Glenmark will pay $29.6 million to settle.

Dozens of US states accuse generic drugmakers — including India-based Glenmark — of coordinating prices in a market meant to stay cheap.

Glenmark admits no wrongdoing, continuing a decade-long, multistate probe into the generics industry.

Sources: STAT